T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine:A case report  

作　　者：Sungwoo Park Eun Jeong Jeong Jung Hun Kang Gyeong-Won Lee Se-Il Go Dong-Hyun Lee Eun-Ha Koh 

机构地区：[1]Division of Hematology and Oncology,Department of Internal Medicine,Gyeongsang National University Hospital,Gyeongsang National University School of Medicine,Gyeongsang National University,Jinju 52727,South Korea [2]Department of Internal Medicine,Institute of Health Sciences,Gyeongsang National University Changwon Hospital,Gyeongsang National University School of Medicine,Changwon 52828,South Korea [3]Department of Laboratory Medicine,Gyeongsang National University Hospital,Gyeongsang National University School of Medicine,Gyeongsang National University,Jinju 52828,South Korea

出　　处：《World Journal of Clinical Cases》2023年第26期6200-6205,共6页世界临床病例杂志

摘　　要：BACKGROUND Mixed-phenotype acute leukemia(MPAL)is characterized by acute undifferentiated leukemia with blasts co-expressing myeloid and lymphoid antigens.However,consensus regarding the ideal management strategy for MPAL is yet to be established,owing to its rarity.CASE SUMMARY A 55-year-old male was diagnosed with T/myeloid MPAL.Vincristine,prednisolone,daunorubicin,and L-asparaginase were administered as induction chemotherapy.Septic shock occurred 10 days after induction,and bone marrow examination following recovery from sepsis revealed refractory disease.Venetoclax and decitabine were administered as chemotherapy-free induction therapy to reduce the infection risk.There were no serious infections,including febrile neutropenia,at the end of the treatment.After receiving two additional cycles of venetoclax/decitabine,the patient underwent haploidentical peripheral blood stem-cell transplantation and achieved complete response(CR)to treatment.CONCLUSION CR was maintained in a patient with MPAL who underwent haploidentical peripheral blood stem-cell transplantation after additional venetoclax/decitabine cycles.

关 键 词：Mixed-phenotype acute leukemia Venetoclax DECITABINE Case report 

分 类 号：R733.71[医药卫生—肿瘤]